Axa
AMPH icon

Axa’s Amphastar Pharmaceuticals AMPH Stock Holding History

Axa’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-29,678
Closed -$1.3M – 1062
2024
Q1 		$1.3M Sell
29,678
-2,500
-8% -$129K ﹤0.01% 809
2023
Q4 		$1.99M Sell
32,178
-30,722
-49% -$1.61M 0.01% 735
2023
Q3 		$2.89M Sell
62,900
-12,700
-17% -$693K 0.01% 648
2023
Q2 		$4.34M Sell
75,600
-76,255
-50% -$3.38M 0.01% 585
2023
Q1 		$5.69M Buy
151,855
+2,449
+2% +$80.3K 0.02% 531
2022
Q4 		$4.19M Buy
149,406
+3,141
+2% +$91.2K 0.02% 649
2022
Q3 		$4.11M Buy
146,265
+66,396
+83% +$2.17M 0.02% 616
2022
Q2 		$2.78M Buy
+79,869
New +$2.85M 0.01% 717

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Axa's AMPH Position: Q2 2024 in Review

Axa sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2024, closing a stake of 29,678 shares — an estimated $1.3M sold.

Axa first reported a position in AMPH in Q2 2022 and held it in 8 quarters. The position peaked at $5.69M in Q1 2023. 269 funds tracked by Wall St. Rank hold AMPH as of Q2 2024.

  • Axa reported no remaining Amphastar Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Axa sold 29,678 Amphastar Pharmaceuticals shares in Q2 2024, an estimated $1.3M.
  • Axa first reported a position in Amphastar Pharmaceuticals in Q2 2022 and held it in 8 quarters.
  • Axa's Amphastar Pharmaceuticals position peaked at $5.69M in Q1 2023.
  • 269 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2024.

Based on Axa's 13F filing for Q2 2024, filed 14 Aug 2024.